Comparative Pharmacology
Head-to-head clinical analysis: BENYLIN versus PERIACTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENYLIN versus PERIACTIN.
BENYLIN vs PERIACTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENYLIN (diphenhydramine) is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating allergic symptoms. It also crosses the blood-brain barrier and acts as a central nervous system depressant via inhibition of histamine and acetylcholine, producing sedative, antiemetic, and antitussive effects.
Cyproheptadine is a first-generation antihistamine with anticholinergic and antiserotonergic properties. It acts as a competitive antagonist at histamine H1 receptors and serotonin 5-HT2 receptors, thereby inhibiting histamine-mediated allergic symptoms and serotonin-mediated effects such as increased gastrointestinal motility and vascular permeability.
Oral: 10-20 mL (25-50 mg diphenhydramine) every 4-6 hours; maximum 100 mg per day.
4 mg orally three times daily; adjust as needed. Maximum: 32 mg/day.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; extended to 10-12 hours in hepatic impairment, increasing risk of accumulation.
10-12 hours terminal elimination half-life; steady-state reached in 2-3 days
Renal: ~80% as unchanged drug and glucuronide conjugates; fecal/biliary: ~20%.
Renal (40-50% as metabolites, <5% unchanged); biliary/fecal (minor, ~10-20%)
Category C
Category C
Antihistamine
Antihistamine